Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4854)
•••
  • nozzpackX
Comment by nozzpackon Dec 01, 2021 4:50pm
148 Views
Post# 34187214

RE:RE:Isotrentoin Market in US had 17.8 % Growth 2021

RE:RE:Isotrentoin Market in US had 17.8 % Growth 2021
In July 2018, the Company amended its distribution and supply agreement [the “Sun Amendment”] with Sun for Absorica.

The Sun Amendment provides Sun with the ability to launch new isotretinoin products prior to the expiration of the agreement in November 2022.

The Company will receive a royalty until December 2024 based on U.S. net sales from Sun’s isotretinoin product portfolio.

In addition, the Absorica New Drug Application [“NDA”] will be returned to the Company on expiry of the agreement in November 2022.

On February 3, 2020, Sun launched their new isotretinoin products under the brand name of Absorica LD.
, 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities